Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants

Latham & Watkins LLP represented 4D Molecular Therapeutics in an underwritten securities offering and provided regulatory, tax, benefits, data privacy, and intellectual property advice to the company. 4D Molecular Therapeutics (Nasdaq: FDMT) priced an underwritten offering of 8,385,809 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 shares of common stock. The shares of common stock are being sold at a price of US$10.51 per share and the pre-funded warrants are being sold at US$10.5099 per pre-funded warrant, reflecting the per‑share price less the US$0.0001 per share exercise price for each pre-funded warrant. The gross proceeds from the offering are expected to be approximately US$100 million before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and pre-funded warrants in the offering are to be sold by 4D Molecular Therapeutics. The offering is expected to close on November 7, 2025, subject to satisfaction of customary closing conditions. Latham & Watkins LLP represented 4D Molecular Therapeutics with a team composed by: Mark Roeder (Bay Area partner, corporate); John Williams (Bay Area partner, corporate); Raul Gonzalez-Casarrubias (associate, corporate); Lexi Zintel (associate, corporate); Keran Huang (associate, corporate); Elizabeth Richards (Washington, D.C. partner, regulatory); Betty Pang (Bay Area partner, regulatory); Chad Jennings (Washington, D.C. counsel, regulatory) with Evan Miller (associate, regulatory); Heather Deixler (Bay Area partner, data privacy and cybersecurity) with Sarah Zahedi (associate, data privacy and cybersecurity); Grace Lee (Bay Area partner, tax) with Dennis Poehland (associate, tax); Maj Vaseghi (Bay Area partner, benefits and compensation); and Christopher Hazuka (San Diego/Bay Area partner, intellectual property) with Robert Yeh (San Diego counsel, intellectual property) and Kristina Funahashi (associate, intellectual property).

Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads